Peter Attia AMA #84: Family History, NAD Skepticism, and Dementia Risk

Peter Attia’s latest AMA opens with a finding that surprises many: for most people, a carefully documented family health history is more predictive of disease risk than a consumer genetic test.

Context

AMA #84 — episode 390 of The Drive — covers seven intersecting topics, from cardiovascular prevention to supplement skepticism. The common thread is decision-making under uncertainty: how much should personal health interventions be driven by population-level evidence, individual risk profiles, or family precedent? The episode arrives as NAD supplementation continues to dominate biohacking circles, with NMN and NR compounds marketed as evidence-based longevity interventions.

Attia’s previous AMAs have mapped his frameworks for peptide therapy, GLP-1 pharmacology, and risk-adjusted longevity planning. This one is more foundational: before optimizing with supplements, understand the risk landscape you’re actually managing.

The Detail

On family health history, Attia argues that the polygenic nature of most chronic diseases — where risk is distributed across hundreds of genetic variants rather than concentrated in a single gene — makes consumer genetic panels largely unhelpful for most conditions. Structured family history assessment, conducted person-by-person and disease-by-disease, extracts more signal. The key question isn’t whether a relative had a condition, but whether they were on medication for hypertension, dyslipidemia, or blood glucose management — indicators of subclinical disease that a simple survey would miss.

On heart disease prevention, the episode addresses why cardiovascular disease persists despite effective prevention tools. Attia’s argument centers on risk tolerance: many people and clinicians don’t intervene early because the trade-off between treating a risk factor and tolerating side effects feels unfavorable, even when the asymmetry favors action. There is a cost to inaction, not just a cost to treatment.

On NAD supplements — NMN and NR specifically — Attia maintains his skeptical position. The mechanism is plausible: NAD declines with age, and replenishing it theoretically supports cellular energy metabolism and DNA repair. But oral bioavailability remains contested, and human trials haven’t demonstrated meaningful clinical outcomes beyond elevated blood NAD levels. Attia states he would need robust data on outcomes that matter — not biomarker proxies — before recommending these products. That threshold hasn’t been met as of this episode.

On dementia risk reduction, the highest-yield interventions in Attia’s framework are exercise, sleep quality, and cardiometabolic health. Personalization matters: where to focus depends on which of those three is most underdeveloped for the individual, not on a fixed supplement stack.

On strength training efficiency, the episode addresses time-constrained practitioners. Attia’s guidance emphasizes prioritizing exercises by functional importance and allowing adequate recovery over maximizing volume — a minimum effective dose framing for people who cannot train daily.

Source: Peter Attia MD

Content created with AI assistance and reviewed for accuracy.